Dr. Jerome R. Obed, DO
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 521
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Florida College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license OS9463
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 521
- Services billed
- 23,700
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 6,800 | 85 |
| Professional service for preparation and provision of 1 or more antigens | 2,028 | 13 |
| Destruction of precancer skin growth, 2-14 growths | 1,158 | 170 |
| Established patient office or other outpatient visit, 20-29 minutes | 776 | 338 |
| Destruction of precancer skin growth, 1 growth | 406 | 240 |
| Destruction of skin growth, 1-14 growths | 255 | 188 |
| Biopsy of related skin growth, first growth | 245 | 176 |
| Established patient office or other outpatient visit, 30-39 minutes | 190 | 133 |
| New patient office or other outpatient visit, 30-44 minutes | 117 | 117 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 95 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Fort Lauderdale, FL | 104 |
| Triamcinolone Acetonide Other prescribers in Fort Lauderdale, FL | 97 |
| Ammonium Lactate Other prescribers in Fort Lauderdale, FL | 80 |
| Hydroxyzine Hcl Other prescribers in Fort Lauderdale, FL | 75 |
| Fluorouracil Other prescribers in Fort Lauderdale, FL | 71 |
| Clobetasol Propionate Other prescribers in Fort Lauderdale, FL | 67 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 48 |
| Mupirocin Other prescribers in Fort Lauderdale, FL | 46 |
| Ciclopirox Other prescribers in Fort Lauderdale, FL | 40 |
| Hydrocortisone Other prescribers in Fort Lauderdale, FL | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 200 payments worth $53,008 in total to this clinician.
| Convatec Inc. | $49,288 |
|---|---|
| Janssen Biotech, Inc. | $775 |
| AbbVie Inc. | $432 |
| Galderma Laboratories, L.P. | $410 |
| Regeneron Healthcare Solutions, Inc. | $358 |
| Pfizer Inc. | $247 |
| UCB, Inc. | $241 |
| Sun Pharmaceutical Industries Inc. | $193 |
| Debt forgiveness | $26,500 |
|---|---|
| Consulting Fee | $18,225 |
| Food and Beverage | $5,119 |
| Travel and Lodging | $3,070 |
| Education | $95.12 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Convatec Inc. Oct 31, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $6,300 |
| Convatec Inc. Apr 2, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $5,963 |
| Convatec Inc. Dec 5, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $3,038 |
| Convatec Inc. Feb 26, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,925 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Convatec Inc. Dec 5, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $3,038 |
| Convatec Inc. Dec 5, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to BRADENTON, FL | $268 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,800 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $1,700 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $1,400 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $1,400 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $1,400 |
| Convatec Inc. Nov 27, 2025 | Debt forgiveness INNOVAMATRIX AC · ADVANCED WOUND CARE | $1,000 |
| Convatec Inc. Oct 31, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $6,300 |
| Convatec Inc. Oct 31, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to CHARLESTON, SC | $103 |
| Convatec Inc. Oct 11, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to CHARLESTON, SC | $798 |
| Convatec Inc. Oct 11, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to CHARLESTON, SC | $547 |
| Convatec Inc. Oct 11, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to CHARLESTON, SC | $343 |
| Regeneron Healthcare Solutions, Inc. Aug 4, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $85.47 |
| Convatec Inc. Apr 2, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $5,963 |
| Convatec Inc. Apr 2, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to TAMPA, FL | $65.69 |
| Convatec Inc. Mar 15, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to TAMPA, FL | $560 |
| Convatec Inc. Feb 26, 2025 | Consulting Fee INNOVAMATRIX AC · ADVANCED WOUND CARE | $2,925 |
| Convatec Inc. Feb 26, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to NASHVILLE, TN | $316 |
| Convatec Inc. Feb 26, 2025 | Travel and Lodging INNOVAMATRIX AC · ADVANCED WOUND CARE · travel to NASHVILLE, TN | $67.55 |
| AbbVie Inc. Jan 21, 2025 | Education in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $656,671 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
Eli Lilly and Company - Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur Inc. · Recruiting · NCT06316297 - A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly and Company - A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company · Terminated · NCT05911841 - A phase 4, prospective, open-label, single arm study to assess the effectiveness of tirzepatide after initiation of ixekizumab in adult participants with moderate-to-severe plaque psoriasis and obesity or overweight i…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.